GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (NAS:IBIO) » Definitions » Cyclically Adjusted PB Ratio

iBio (IBIO) Cyclically Adjusted PB Ratio : 0.00 (As of May. 29, 2025)


View and export this data going back to 2008. Start your Free Trial

What is iBio Cyclically Adjusted PB Ratio?

As of today (2025-05-29), iBio's current share price is $0.7821. iBio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $293.08. iBio's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for iBio's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, iBio's highest Cyclically Adjusted PB Ratio was 7.00. The lowest was 0.01. And the median was 0.76.

IBIO's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.485
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

iBio's adjusted book value per share data for the three months ended in Mar. 2025 was $1.131. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $293.08 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


iBio Cyclically Adjusted PB Ratio Historical Data

The historical data trend for iBio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Cyclically Adjusted PB Ratio Chart

iBio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.82 1.76 0.30 0.03 0.01

iBio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of iBio's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, iBio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iBio's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iBio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where iBio's Cyclically Adjusted PB Ratio falls into.


;
;

iBio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

iBio's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.7821/293.08
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iBio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, iBio's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.131/134.9266*134.9266
=1.131

Current CPI (Mar. 2025) = 134.9266.

iBio Quarterly Data

Book Value per Share CPI Adj_Book
201506 748.733 100.684 1,003.378
201509 653.933 100.392 878.889
201512 525.200 99.792 710.109
201603 486.176 100.470 652.909
201606 552.056 101.688 732.505
201609 396.722 101.861 525.504
201612 230.722 101.863 305.613
201703 719.222 102.862 943.419
201706 495.222 103.349 646.533
201709 331.211 104.136 429.144
201712 339.652 104.011 440.608
201803 180.609 105.290 231.447
201806 505.188 106.317 641.134
201809 352.189 106.507 446.166
201812 291.632 105.998 371.224
201903 177.103 107.251 222.805
201906 61.575 108.070 76.877
201909 -40.271 108.329 -50.158
201912 -4.688 108.420 -5.834
202003 18.447 108.902 22.855
202006 202.207 108.767 250.839
202009 221.756 109.815 272.466
202012 253.149 109.897 310.806
202103 242.697 111.754 293.020
202106 249.048 114.631 293.141
202109 230.603 115.734 268.844
202112 207.794 117.630 238.350
202203 182.064 121.301 202.515
202206 145.608 125.017 157.150
202209 107.484 125.227 115.810
202212 30.458 125.222 32.819
202303 21.984 127.348 23.292
202306 15.139 128.729 15.868
202309 9.551 129.860 9.924
202312 2.835 129.419 2.956
202403 2.919 131.776 2.989
202406 2.473 132.554 2.517
202409 2.055 133.029 2.084
202412 1.516 133.157 1.536
202503 1.131 134.927 1.131

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


iBio  (NAS:IBIO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


iBio Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of iBio's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


iBio Business Description

Industry
Traded in Other Exchanges
N/A
Address
11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Executives
Gary Sender director C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Felipe Duran officer: Interim CFO 8800 HSC PARKWAY, BRYAN TX 77807
William D Clark director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Evert B. Schimmelpennink director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd director, officer: CEO and Executive Chairman C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz officer: See Remarks 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux officer: Chief Operating Officer 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova director RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Linda Washington Armstrong director 8800 HSC PARKWAY, BRYAN TX 77807
John Delta officer: Principal Accounting Officer 8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin officer: President C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney officer: Chief Financial Officer C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431